✉ Email this page to a colleague
« Back to Dashboard
Ambroxol is an investigational drug.
There have been 25 clinical trials for Ambroxol. The most recent clinical trial was a Phase 3 trial, which was initiated on August 1st 2007.
The most common disease conditions in clinical trials are Pharyngitis, Parkinson Disease, and Dementia. The leading clinical trial sponsors are Boehringer Ingelheim, Sanofi, and Hyundai Pharmaceutical Co., LTD.
Recent Clinical Trials for Ambroxol
|Ambroxol as a Disease-modifying Treatment in GBA-PD||IRCCS National Neurological Institute "C. Mondino" Foundation||Phase 2|
|Ambroxol as a Disease-modifying Treatment in GBA-PD||University of Campania "Luigi Vanvitelli"||Phase 2|
|Ambroxol as a Disease-modifying Treatment in GBA-PD||Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta||Phase 2|